Cocrystal Pharma, Inc.

Name: Cocrystal Pharma, Inc. standardized financial statements, quarterly
Creator: Listed

COCPNasdaqCIK 1412486HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$105.0k, Q2 FY2026

Operating income−$3.2m, Q2 FY2026

Net income−$3.2m, Q2 FY2026

Cocrystal Pharma, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	225	105
Cost of revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	4,194	4,267	2,950	4,308	3,242	2,037	1,360	1,122	954	1,619	1,371	2,142
Operating income	$k	(4,443)	(4,666)	(4,158)	(5,448)	(5,042)	(3,230)	(2,341)	(2,108)	(2,089)	(2,481)	(2,356)	(3,184)
Interest expense	$k	(320)	(180)	(220)	(151)	(111)	(55.0)	(37.0)	(28.0)	(22.0)	(47.0)	(22.0)	(10.0)
Income tax	$k	not reported	not reported	not reported	not reported	0.0	not reported	not reported	not reported	not reported	not reported	0.0	0.0
Net income	$k	(4,165)	(4,464)	(3,956)	(5,343)	(4,939)	(3,266)	(2,301)	(2,055)	(2,049)	(2,426)	(2,299)	(3,164)
Diluted EPS	$ per share	(0.41)	not reported	(0.39)	(0.53)	(0.49)	not reported	(0.23)	(0.20)	(0.19)	not reported	(0.17)	(0.23)
Basic EPS	$ per share	(0.41)	not reported	(0.39)	(0.53)	(0.49)	not reported	(0.23)	(0.20)	(0.19)	not reported	(0.17)	(0.23)

Balance sheet

Cash and equivalents$2.2m, Q2 FY2026

Shareholders' equity$1.0m, Q2 FY2026

Cocrystal Pharma, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	29.7	26.4	21.8	18.1	13.0	9.9	6.9	4.8	7.7	7.0	4.7	2.2
Current assets	$m	32.2	29.1	24.5	19.7	14.3	11.6	8.8	6.8	8.8	8.1	5.9	3.2
Total assets	$m	32.6	31.3	26.5	21.6	16.2	13.5	10.7	8.5	10.4	9.7	7.4	4.6
Current liabilities	$m	1.9	3.3	2.4	2.7	1.9	2.4	1.9	1.8	1.5	2.2	2.2	2.6
Total liabilities	$m	1.9	4.9	4.0	4.2	3.5	3.9	3.4	3.2	2.8	3.4	3.3	3.6
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	30.7	26.4	22.6	17.4	12.7	9.5	7.3	5.3	7.7	6.3	4.1	1.0

Cash flow

Operating cash flow−$2.5m, Q2 FY2026

Capital expenditure$0, Q4 FY2025

Cocrystal Pharma, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(2,681)	(3,326)	(4,503)	(3,699)	(5,123)	(3,160)	(2,939)	(2,155)	(1,362)	(1,736)	(2,340)	(2,516)
Capital expenditure	$k	0.0	59.0	8.0	0.0	0.0	0.0	not reported	not reported	not reported	0.0	not reported	not reported

Diluted shares (weighted)13.79m, Q2 FY2026

Cocrystal Pharma, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	8.1	8.1	10.1	10.2	10.2	10.2	10.2	10.2	10.2	11.0	13.8	13.8

Shares outstanding: 19.26m at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.